key: cord-0898410-e65zas4t authors: Clipman, Steven J; Wesolowski, Amy; Mehta, Shruti H; Cobey, Sarah; Cummings, Derek A T; Solomon, Sunil S title: Improvements in Severe Acute Respiratory Syndrome Coronavirus 2 Testing Cascade in the United States: Data From Serial Cross-sectional Assessments date: 2021-08-10 journal: Clin Infect Dis DOI: 10.1093/cid/ciab683 sha: 2af5ff00830b50028e5901a8651075d2b6946521 doc_id: 898410 cord_uid: e65zas4t BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing is critical for monitoring case counts, early detection and containment of infection, clinical management, and surveillance of variants. However, community-based data on the access, uptake, and barriers to testing have been lacking. METHODS: We conducted serial cross-sectional online surveys covering demographics, coronavirus disease 2019 symptoms, and experiences around SARS-CoV-2 diagnostic testing to characterize the SARS-CoV-2 testing cascade and associated barriers across 10 US states (California, Florida, Illinois, Maryland, Massachusetts, Nebraska, North Dakota, South Dakota, Texas, and Wisconsin), from July 2020 to February 2021. RESULTS: In February 2021, across 10 US states, 895 respondents (11%) reported wanting a diagnostic test in the prior 2 weeks, 63% of whom were tested, with limited variability across states. Almost all (97%) who were tested received their results; 56% received their results within 2 days. In Maryland, Florida, and Illinois, where serial data were available at 4 time points, 56% were tested the same day they wanted or needed a test in February 2021, compared with 28% in July 2020, and 45% received results the same day, compared with 17% in July 2020. Wanting a test was significantly more common among younger, nonwhite respondents and participants with a history of symptoms or exposure. Logistical challenges, including not knowing where to go, were the most frequently cited barriers. CONCLUSIONS: There were significant improvements in access and turnaround times across US states, yet barriers to testing remained consistent across states, underscoring the importance of a continued focus on testing, even amidst mass vaccination campaigns. and virulent variants, such as the delta variant, which that may still cause disease even in vaccinated persons, as is currently being observed in the United States and globally [2] . In addition, some of the most effective therapies against SARS-CoV-2, such as monoclonal antibodies and high-titer convalescent plasma, have been shown to be most efficacious early in the course of infection, highlighting the need for rapid turnaround times to enable early initiation of therapy [3] . Over the past year, testing access across the United States has been hampered by logistics, supply chain problems, and changing recommendations [4] [5] [6] . For example, on 24 August 2020, the Centers for Disease Control and Prevention recommended that asymptomatic persons not be tested even in the setting of potential exposure but reversed the recommendation on 18 September 2020 to reinforce testing for asymptomatic persons [6] . As the pandemic evolved, diagnostics also evolved with the introduction of point-of-care reverse-transcription polymerase chain reaction (RT-PCR) tests (eg, Abbott ID NOW and Cepheid GeneXpert) and rapid antigen tests, dramatically improving access and turnaround times. Most recently, many mass testing sites have been either been shut down or replaced by mass vaccination sites. In this dynamic context, community-based data on testing uptake, turnaround times, and barriers remains critical to the public health response, particularly as educational institutions resume in-person instruction, businesses support increased capacity, and mask mandates are removed. We describe the self-reported barriers and access to SARS-CoV-2 testing in February 2021 across 10 US states with varying SARS-CoV-2 epidemic trajectories (California, Florida, Illinois, Maryland, Massachusetts, North Dakota, South Dakota, Nebraska, Texas, and Wisconsin). Furthermore, in a subset of these states (Florida, Illinois, and Maryland) we used serial cross-sectional surveys to examine changes in the SARS-CoV-2 testing cascade between June 2020 and February 2021. We recruited participants from Florida, Illinois, and Maryland (approximately 1000 per state] for an online survey at 4 time points: waves 1 (15-31 July 2020), 2 (16 September to 15 October 2020), 3 (4-18 December 2020), and 4 (16-28 February 2021). Data from additional states-California, Massachusetts, North Dakota, South Dakota, Texas, and Wisconsin-were captured in survey waves 3 and 4. Data from a pilot wave in Maryland have been previously published [7] and are not included in these analyses because questions on testing were adapted based on responses received in the pilot wave, limiting the ability to compare responses with subsequent waves (Supplementary Figure 1) . States were selected to represent the diversity of the pandemic with respect to daily case counts and statewide orders on nonpharmaceutical interventions. At the time of these surveys, there were no systematic differences in testing availability across these states [8] [9] [10] ; all had public and private options, including free testing that did not require a physician's order. All participants were ≥18 years, provided consent, and resided in the study state. Participants were recruited using Dynata (https://www.dynata.com), one of the largest first-party global data platforms. Dynata maintains a database of potential participants who are randomized to specific surveys if they meet the demographic targets of the survey; in addition, participants could select a survey from a list of potential options (survey topic not provided). Participants received modest compensation for the completion of a survey from Dynata. Security checks and quality verifications include digital fingerprinting and spot-checking via third-party verification. To accrue demographically representative samples, we provided quotas for age, sex, race/ethnicity, and income based on the population composition of the states. All participants completed a self-administered electronic survey that captured information on the following domains: demographics, symptoms of SARS-CoV-2 infection, history of prior SARS-CoV-2 infection, mobility, practice of nonpharmaceutical interventions, and experiences of SARS-CoV-2 testing (PCR, antigen, or antibody testing), ever and in the prior 2 weeks. Questions on testing covered reasons for wanting or needing a test, reasons for not being tested, the type of test received, wait times, quarantine behavior, test results, and hospitalization after positive results. In regard to wanting of needing a test, the survey asked, "In the past 2 weeks, have you wanted or needed a test for COVID-19 [coronavirus disease 2019]?" or "Have you ever wanted or needed a test for COVID-19?" For simplicity, going forward, we will classify participants responding "yes" to either of these questions as "wanting" a test. The same instrument was used across waves 1-4, and the survey was hosted using SurveyMonkey with in-built data skips, logic checks, and field restrictions to minimize errors. For all analyses, we focused on SARS-CoV-2 diagnostic testing (RT-PCR) in the prior 2 weeks to minimize recall bias and reflect current testing access. Initial analyses focused on the most recent wave of data collection, in which 10 states were sampled from 16 to 28 February 2021. We used χ2 and Mann-Whitney tests to compare categorical and continuous variables, respectively, by testing behaviors. Logistic regression analysis was used to analyze associations with 2 outcomes: (1) self-report of wanting a SARS-CoV-2 test among all sampled and (2) receipt of a test among those who wanted a test. Variables were considered for inclusion in multivariable analyses if they were biologically of epidemiologically significant or associated in univariable analysis at P < .10; age, sex, and race/ethnicity were included regardless of statistical significance. Additional variables considered included household size, SARS-CoV-2 infection in a household member, education, annual household income, employment and essential worker status, self-reported exposure and/or symptoms, report of travel, urban-rural classification, and state. Residential zip code and the National Center for Health Statistics urban-rural classification scheme [11] were used for urban-rural classification. Additional analyses compared testing outcomes and testing barriers across the 4 waves of data collection. Two-proportion z tests were used to compare changes over waves. Survey weights were applied to all analyses, using iterative proportional fitting to further reflect the composition of the study states with respect to age, sex, race/ethnicity, income, and education using the Census Bureau's American Community Survey [12] . Weighting variables were raked according to their marginal distributions, as well as by 2-way cross-classifications for each pair of demographic variables. Statistical analyses were carried out using Python (version 3.7.3) and R (version 3.5.1) software. This study was approved by the Johns Hopkins Bloomberg School of Public Health institutional review board. Among 8029 persons sampled in the most recent survey wave 4 (February 2021) across 10 US states (Florida, Illinois, Maryland, California, Massachusetts, North Dakota, Nebraska, South Dakota, Texas, and Wisconsin), the median age was 45 (range, 41 [Texas] to 48 [Florida]) years, and 50% reported female sex across all states. Overall, 13% of respondents were non-Hispanic black, and 25% were Hispanic of any race. The proportion of black respondents was highest (30%) in Maryland, and California had the largest proportion of Hispanic respondents (40%). Of the respondents, 39% reported working outside the home. About 38% had either a high school education or less, and about a third (34%) had an annual household income below US $40 000. Detailed demographic characteristics by wave are provided in Supplementary Table 2 . In February 2021, 895 (11%) of 8029 participants across 10 states reported wanting a SARS-CoV-2 diagnostic test in the prior 2 weeks. The median age of participants wanting a test was 37 years (interquartile range, 20-48 years), and the majority (54%) were male; 40% self-identified as white, and 58% reported working outside the home ( Table 1 ). The reasons cited for wanting a test (nonexclusive) were a positive or symptomatic household member (32%), symptoms (28%), close contact with a positive or symptomatic person (26%), desire to know one's status (25%), required for school or work (15%), and before (13%) or after (10%) travel. In multivariable analyses, self-report of wanting a SARS-CoV-2 test in the prior 2 weeks was significantly more common among younger participants (adjusted odds ratio [ Table 3) . Of 895 participants who wanted a test, 63% (559) were tested, with no significant differences by state (Figure 1 ). In Table 1 895 (11) 181 (12) 118 (11) 118 (11) 98 (12) 79 (11) 12 (5) 31 (9) 178 (12) 80 (10) Age Table 4 ). Of the 559 participants who were tested in wave 4, 56% were tested the same day they wanted a test and 42% received their results the same day ( Figure 2 ). Among the 336 who reported wanting a test but were not tested, the most frequently cited barrier was not knowing where to go (27%), followed by not having time (20%) and inability to obtain a physician's order (16%) ( Table 1) . We observed improvements in the proportion of respondents tested among those wanting a test across waves 1-4 (July 2020 to February 2021) in Florida, Illinois, and Maryland, increasing from 52% in July to 62% in February (P < .01) ( Table 2) . We also saw significantly improved wait times ( Figure 3) . The proportion of respondents tested the same day they wanted a test increased from 28% in July 2020 to 56% in February 2021, and the proportion who received results the same day they were tested increased from 17% to 45% (both P < .01). The total time from wanting a test to receiving results was ≤2 days for 56% of respondents in February 2021, compared with 23% in July 2020 (P < .01). Despite these improvements, 42% of respondents who wanted a test still waited ≥3 days from wanting a test to being tested and receiving results. While the proportion of respondents tested among those who wanted a test increased from July 2020 to February 2021, barriers remained relatively stable. The most commonly and consistently reported barrier was not knowing where to go ( Table 2) . Of 8029 participants surveyed across 10 US states in February 2021, 11% reported wanting a SARS-CoV-2 test in the prior 2 weeks, 62% of whom were able to be tested with no significant differences by state. It was encouraging to see improvements from July 2020 to February 2021 in the 3 states (Florida, Illinois, and Maryland) where we had longitudinal data over the entire period. Specifically, we saw significant improvements in access to testing among those who wanted to be tested and striking decreases in turnaround time. Despite these improvements, barriers to testing access persisted over time and were relatively consistent across states. Most striking in these data was the improved testing turnaround times and specifically the proportions receiving sameday testing and same-day results, which essentially doubled from July 2020 to February 2021. Across Maryland, Florida, and Illinois, the proportion who received their results on the same day they wanted a test improved from 11% in July 2020 to 33% in February 2021. In contrast, those waiting >1 week declined from a high of 52% in September/October to 14% in February 2021. This likely reflects a combination of increased numbers of mass testing sites, as well as the introduction of point of care RT-PCR testing and rapid antigen testing. Of equal importance, however, is that barriers to testing did not appreciably change over time from July 2020 to February 2021. For example, although a physician's order was not required for testing, 16% of respondents reported being turned away or were unable to be tested owing to lack of a physician's order. Logistical issues-including not knowing where to go and/or distance to a testing center and/or not having time to go for a test-were the most commonly cited barriers in February 2021. The conversion of mass testing sites into vaccination sites may further exacerbate access to testing, as has already been suggested by media reports [13, 14] . Furthermore, reports also suggest that some private practices have stopped testing for COVID-19, owing to low insurance reimbursements [15] . Therefore, it is likely given these changes, access to SARS-CoV-2 testing may have declined in the United States after the study period. Programs could leverage electronic platforms (eg, Google Display Network, Facebook, and Instagram) with the ability to deliver messaging targeted to an individuals' location thereby, informing the user of nearby testing sites and/or the importance of testing in zip codes with high case positivity. As the vaccine rollout continues and case counts continue to decline, it is likely that the demands around testing may also decline. Yet, testing will remain critical for the foreseeable future. First, even with the dramatic success of the current vaccines, much remains unknown, including the durability of the vaccine-associated immune response and the efficacy against emerging variants [16] . This uncertainty-combined with the relaxing of nonpharmaceutical interventions, such as mask mandates-highlights the importance of ensuring continued access to testing services for pandemic control [17] . Second, the SARS-CoV-2 pandemic in most countries globally is monitored via passive surveillance using case counts and case positivity rates, both of which rely heavily on testing programs and data. Facilitating timely access to testing will ensure early detection of increasing case counts and/or variants of concern, allowing for early interventions to prevent nationwide and global surges. Third, novel therapeutic agents, such as monoclonal antibodies, require administration within days of infection for maximum efficacy, again reinforcing the need for timely and accessible testing [18, 19] . It is critical to continue to monitor uptake of testing and develop new messaging and strategies to improve testing in the current context. This is particularly important as case counts escalate owing to the emergence of novel variants, stressing the need for clear communication on how to access a SARS-CoV-2 diagnostic test. For example, the possibility of infection after vaccination needs to be communicated, especially the possibility of asymptomatic, mild, or moderate infections. While it is impossible not to feel optimistic about the "return to normal" given the direction the United States is going with the vaccine rollout, case count declines, and lifting of restrictions, it is prudent to not lose sight of core infectious disease principles. Active and/or passive surveillance of case counts is of paramount importance as are the basic principles of detection, contact tracing, and isolation. There are limitations of online surveys; individuals need internet access to participate, so these surveys may underrepresent lower-income or less-educated individuals. However, in a constantly evolving pandemic where face-to-face data collection is nearly impossible, this approach allows for the rapid and safe collection of individual-level data across diverse geographies and demographics. If anything, we are likely overestimate access to testing. Moreover, care was taken to balance targets on state demographic characteristics, including the use of survey weights, and estimates of flu vaccine coverage were comparable coverage in to samples based on random digit dialing [7] . In addition, there is a possibility that respondents misclassified the type of test. Overall, however, these findings are in line with the scale-up of diagnostic testing in the United States and with evidence reported by other studies [5, 20, 21] . Data represent % of respondents unless otherwise specified. c Respondents could select >1 reason for not being tested for survey waves 2-4. For survey wave 1, they selected the primary reason. d For survey waves 2-4, participants were asked to specify other reasons, which were recoded where appropriate. These data highlight important improvements in access, uptake, and turnaround time of SARS-CoV-2 testing in the United States. Simultaneously, these data highlight persistent and common testing barriers across US states and underscore the importance of amplifying messaging and access to testing. Clear messaging on who, when, where, and how to be tested and continued access to testing are particularly important for monitoring variant spread and breakthrough infections (an early signal of vaccine durability) in the current context of relaxing mask mandates, increased mobility, and summer travel. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset About variants of the virus that causes COVID-19 Early high-titer plasma therapy to prevent severe Covid-19 in older adults Covid-19: ensuring equality of access to testing for ethnic minorities Geographic access to United States SARS-CoV-2 testing sites highlights healthcare disparities and may bias transmission estimates Overview of testing for SARS-CoV-2 (COVID-19) Rapid real-time tracking of nonpharmaceutical interventions and their association with SARS-CoV-2 positivity: the COVID-19 pandemic pulse study Maryland Department of Health. MD COVID-19 testing sites Florida COVID-19 testing sites Illinois Department of Public Health. COVID-19 testing sites NCHS urban-rural classification scheme for counties 5-year estimates now available US vaccinations are increasing, but what happened to COVID-19 testing? ABC News A decline in testing may be masking the spread of the virus in some U.S. states Burned by low reimbursements, some doctors stop testing for COVID Fast-spreading COVID variant can elude immune responses When you've been fully vaccinated: how to protect yourself and others REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19 A neutralizing monoclonal antibody for hospitalized patients with Covid-19 Geographic and demographic heterogeneity of SARS-CoV-2 diagnostic testing in Illinois, USA Rapid scaling up of Covid-19 diagnostic testing in the United States-the NIH RADx initiative Acknowledgments. The authors gratefully acknowledge Adebola Adegbesan, who worked closely with our team in the recruitment of the study sample.Disclaimer. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Johns Hopkins University or the National Institutes of Health. Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.